IFNG and congenital rubella syndrome: Given the crucial role of IFN-γ in CRS, clinical studies have demonstrated the efficacy of the IFN-γ monoclonal antibody emapalumab in controlling CAR-T induced CRS, which has been confirmed in relevant case reports [16, 47].